Cesar Rodriguez Valdes, MD, Mount Sinai Hospital, New York, NY, shares the key results of the post hoc analysis of the GRIFFIN study evaluating the addition of daratumumab to lenalidomide, bortezomib and dexamethasone (D-RVd) and autologous stem cell transplant (ASCT) to induction, consolidation and maintenance therapy versus lenalidomide, bortezomib and dexamethasone (RVd) with ASCT in patients with newly diagnosed multiple myeloma (NCT02874742), discussing depth of response, measurable residual disease (MRD), and the future of quadruplet therapy in multiple myeloma. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

свернуть